Immunic (IMUX)
(Delayed Data from NSDQ)
$1.83 USD
-0.12 (-6.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.84 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
IMUX 1.83 -0.12(-6.15%)
Will IMUX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMUX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMUX
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
IMUX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMUX
Biotech Alert: Searches spiking for these stocks today
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Buy Rating Affirmed for Immunic, Inc. on Promising MS Drug Developments and Favorable Market Position
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Immunic initiated with bullish view at EF Hutton, here's why